SiBone (NASDAQ:SIBN) Stock: Insider Michael Pisetsky Sells 29,665 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 29,665 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $22.11, for a total transaction of $655,893.15. Following the transaction, the senior vice president owned 164,444 shares in the company, valued at approximately $3,635,856.84. The trade was a 15.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SiBone Stock Up 17.6%

Shares of SIBN opened at $23.77 on Wednesday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a 12 month low of $11.48 and a 12 month high of $23.93. The firm’s 50 day moving average is $19.50 and its 200-day moving average is $16.48. The stock has a market capitalization of $1.05 billion, a PE ratio of -76.67 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. Equities research analysts forecast that SiBone will post -0.40 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SIBN. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. UBS Group raised their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial boosted their price target on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Needham & Company LLC cut their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, TD Cowen upped their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, SiBone presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Key Headlines Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results topped expectations. SI-BONE reported a loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million slightly exceeded estimates and grew 14.5% year over year. Si-BONE Q3 earnings
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume rose about 20%, and the active U.S. physician base expanded 16% to 1,770. Adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow was $5.9 million. The company also cited new product and reimbursement developments that could support adoption. SI-BONE Q3 results and guidance
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25. TD Cowen raised its target to $23 from $20, though that target is below the recent share price. UBS analyst rating
• Neutral Sentiment: 2026 revenue guidance was reaffirmed. SI-BONE forecast revenue of $231 million to $233 million, close to the $232.2 million consensus, so the outlook offered little change from expectations. The company reported a $3.6 million net loss and remains unprofitable.
• Negative Sentiment: Two insiders sold shares. SVP Michael Pisetsky sold 29,665 shares, and Anshul Maheshwari sold 3,738 shares. Both retained sizable holdings, but the sales may weigh modestly on sentiment. Insider sale filing

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC raised its stake in SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after acquiring an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC boosted its stake in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its stake in shares of SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after purchasing an additional 598,300 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after purchasing an additional 182,465 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after purchasing an additional 238,219 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.